RESILIENCE helps you survive cancer with a strong heart

The Therapy

Remote Ischemic Conditioning

Remote Ischemic Conditioning is a phenomenon by which brief, reversible episodes of occlusion and re-occlusion in one organ (e.g. an arm) render remote organs resistant to injury. Remote Ischemic Conditioning has been tested in myocardial infarction, stroke, and cardiac surgery settings, involving thousands of participants proving to be extremely safe. Remote Ischemic Conditioning is implemented by using a non-invasive tool similar to a blood pressure device and can be applied by the patient itself at home.

Remote Ischemic Conditioning Device

The RESILIENCE study will be the first large trial to test the benefits of Remote Ischemic Conditioning in the context of anthracycline-induced cardiotoxicity.

The main hypothesis of RESILIENCE trial is that the application of weekly Remote Ischemic Conditioning during the span of the chemotherapy duration will reduce the incidence of anthracycline-induced cardiotoxicity and heart failure. This hypothesis is based on strong pre-clinical data. In an experimental model, the implementation of Remote Ischemic Conditioning before each administration of anthracyclines resulted in a massive protection against the development of heart failure.

Benefits and mechanism of protection of Remote Ischemic Conditioning applied before each administration of anthracyclines in a large animal model (RIPC stands for Remote Ischemic PreConditioning). Figure taken from Cardiovasc Res. 2021;117:1132-1143.

In RESILIENCE, Remote Ischemic Conditioning protocol will consist of 4 cycles of arm cuff inflation followed by deflation. Each cycle lasts 10 minutes (5 minutes inflation and 5 minutes deflation of the cuff). Therefore, the intervention will last for 40 min each time.

Protocol of Remote Ischemic Conditioning in RESILIENCE: 4 cycles of 5-min inflation / 5 min deflation of the arm cuff

Logotipo Resilience

Are you a patient participating in RESILIENCE? Here you will find useful information about the details of your participation, activities specifically designed for you. You will also be able to contact RESILIENCE researchers.

In accordance with the provisions of Regulation (EU) 2016/679 on the protection of personal data of natural persons (GDPR), the personal information you have provided will be incorporated into the data processing systems of the Centro Nacional de Investigaciones Cardiovasculares Carlos III (F.S.P.) for the purpose of attending your registration application in the restricted area for patients participating in the RESILIENCE study. The legal basis for processing your personal data for this purpose is your explicit consent. Your personal data will not be disclosed to any recipients other than those to whom you authorise or when required by law to do so. You may exercise your rights of access, right to rectification, to object, to erasure, to restriction of processing, data portability and not to be subject to automated individual decision-making. To exercise these rights, as well as to obtain additional information about the processing of your personal data, you can consult the following link Terms and Conditions